A Randomized Controlled Trial to Determine the Role of Biomarkers in Surveillance for Hepatocellular Carcinoma (HCC)
The objective of this study is to evaluate the clinical effectiveness of biomarkers,
alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and
des-gamma-carboxy prothrombin (DCP), for surveillance program patients whose hepatocellular
carcinoma (HCC) development may be potentially missed by ultrasound (US). This study expects
to demonstrate that addition of biomarkers will increase the detection rate by at least 10%.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society